Novartis Biomedical Research, Cambridge (United States of America)
Follow
Contributor content
Presentation
A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of XXB750 in heart failure patients with reduced or mildly reduced ejection fraction
